AI in Medicine News — 2026-10-18 (Sun) Evening News

Overview

Diagnostics and imaging, and drug discovery, saw the most movement in this period. Headlines covered a breast MRI meta-analysis urging caution, an FDA clearance for a Tempus AI product, and an insitro and AstraZeneca partnership worth up to $1.5B. Safety and agentic AI in healthcare were also discussed (Bioengineer.org, The National Law Review, Dealroom, Techeconomy).

Diagnostics and imaging

- A new meta-analysis finds AI reads breast MRI with "striking accuracy" but urges caution. The headline gives no figures, and the evidence is a meta-analysis (Bioengineer.org). - A piece asks what turns an AI pathology tool into a companion diagnostic. It is a discussion piece, not a study result (Drug Discovery News). - Wafik S. El-Deiry discusses DNA methylation profiling and AI in precision diagnostic pathology (Oncodaily). - AI skin cancer models are reported to burn four times more energy for no extra accuracy (bioengineer.org).

Clinical decision support

- A new framework helps language models track a deadly lung disease over time. The headline gives no performance data (Bioengineer.org). - A piece covers the rise of conversational AI in healthcare (Amazon Web Services (AWS)). 【Generative AI and medical documentation】 - ChatGPT falls short at spotting children's elbow fractures on X-rays (bioengineer.org). - ModMed held its MOMENTUM conference and previewed new AI capabilities for specialty medical practices (FinancialContent). 【Hospital operations and care delivery】 - IIM-Jammu signed an MoU with a US university to advance healthcare AI and innovation (The Tribune). - Two headlines are not directly about hospital operations: AI debt concerns are driving default insurance costs to record highs (https://www.irishsun.com/), and an AI planner supports whole-life costing for UK public building retrofits (Bioengineer.org). 【Drug discovery and clinical trials】 - An AI model predicts stable molecular forms to sharpen drug discovery. The stage is not stated (Bioengineer.org). - Insilico Medicine will showcase AI for drug discovery and longevity at summits in Abu Dhabi and Dubai (EurekAlert!). - insitro and AstraZeneca struck an AI drug-discovery partnership worth up to $1.5B for liver and heart disease. The development stage is not stated (Dealroom). - A virology check finds respiratory virus polymerases "break the benchmarks" of AI drug discovery (Bioengineer.org). - China is considering new export curbs on solar, AI and biotech (The Hindu). 【Medical device approvals and regulation】 - Approval: Tempus received FDA clearance for an AI product. The headline is truncated, so the intended use is not stated (The National Law Review). - No designations or guidance were reported.

Safety, errors and bias

- A Nelson Advisors piece covers the leap from rules-based chat assistants to agentic AI in healthcare, including the "Autonomous Clinical Workforce" (https://www.healthcare.digital/). - A piece argues that agentic AI in healthcare needs a human hand on the button (Techeconomy). - The ChatGPT elbow fracture result and the energy cost of skin cancer models, covered above, are also relevant here (bioengineer.org). 【Research results (major journals)】 - A JAMA-related piece covers how AI is changing medical evidence review and clinical decision-making. The headline gives no findings (Oncodaily).

Developments in Japan

- Yomiuri Shimbun ran a column by editorial writer Ritsuko Inokuma on how AI will change the future of medicine (Yomiuri Shimbun). - Forbes Japan argues that AI will change medicine but humans still hold patients' hands (Forbes JAPAN). - IndexBox forecasts the digital slide scanner market to 2035, with remote pathology diagnosis and AI driving growth (IndexBox). - South Korea's government discussed AI medicine and the vaccine supply chain at the WHO Western Pacific regional meeting (Chosunbiz). - Associate Professor Ha Thi Thanh Huong discusses bringing AI closer to human health (Vietnam.vn).

Statements by key figures

No notable developments.